Allo HSCT Using RIC and PTCy for Hematological Diseases
Public ClinicalTrials.gov record NCT05805605. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.
Study identification
- NCT ID
- NCT05805605
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 56 participants
Conditions and interventions
Conditions
- Acute Myelogenous Leukemia
- Acute Lymphocytic Leukemia
- Biphenotypic Acute Leukemia
- Undifferentiated Leukemia
- Prolymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Plasma Cell Leukemia
- Myelodysplastic Syndromes
- Leukemia, Myeloid
- Myelodysplastic Syndrome With Excess Blasts-1
- Burkitt Lymphoma
- Relapsed T-Cell Lymphoma
- Relapsed Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Myeloproliferative Neoplasm
- Myelofibrosis
Interventions
- Peripheral Blood Stem Cell Transplant Biological
- Allopurinol 300 MG Drug
- Fludarabine Drug
- Cyclophosphamide Drug
- Bone Marrow Cell Transplant Biological
- Total Body Irradiation Radiation
- Sirolimus Pill Drug
- Mycophenolate Mofetil Drug
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- Up to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2023
- Primary completion
- Oct 21, 2027
- Completion
- Oct 21, 2028
- Last update posted
- Jul 5, 2026
2023 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Masonic Cancer Center at University of Minnesota | Minneapolis | Minnesota | 55455 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05805605, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 5, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05805605 live on ClinicalTrials.gov.